Literature DB >> 28088496

Endogenous thrombin potential changes during the first cycle of oral contraceptive use.

Carolyn L Westhoff1, Malcolm C Pike2, Serge Cremers3, Andrew Eisenberger4, Stella Thomassen5, Jan Rosing5.   

Abstract

OBJECTIVES: Venous thromboembolism (VTE) risk increases within months of combination oral contraceptive (COC) initiation. Because elevated endogenous thrombin potential (ETP) has been found in several studies to be a VTE risk factor, we evaluated the extent of ETP changes during the initial cycle of an ethinyl estradiol (EE) and levonorgestrel (LNG) COC. We also assessed the relationship between ETP changes and systemic EE and LNG concentrations. STUDY
DESIGN: Participants provided multiple blood samples during a first 21-day cycle of a 30-mcg EE/150-mcg LNG COC and after a further 7 days without an active COC. Thrombin generation measured with and without addition of activated protein C (APC) yielded ETP+APC and ETP-APC and the normalized APC sensitivity ratio (nAPCsr). EE and LNG pharmacokinetic analyses were conducted over 24 h after the first COC tablet and again at steady state.
RESULTS: Thrombin generation was determined in 16 of the 17 women who completed the study. Mean ETP-APC increased steadily to 21% above baseline at 24 h after the 6th COC tablet (COC624; p<.001) and to 28% above baseline at steady state (COC21; p<.001). The percentage increase in mean ETP+APC was considerably more - 54% at COC624 and 79% at steady state. Mean nAPCsr increased by 28% at COC624 and by 41% at steady state. Higher concentrations of EE or LNG were not correlated with greater increases in ETP.
CONCLUSIONS: ETP increases during the first COC cycle were substantial. IMPLICATIONS: The early increases in ETP may provide biological support for the rapid increase in VTE risk during initial COC use. The lack of association between this clotting system perturbation and the systemic EE concentration is surprising and deserves further study.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endogenous thrombin potential; Oral contraceptives; Protein C; Venous thromboembolism

Mesh:

Substances:

Year:  2017        PMID: 28088496      PMCID: PMC5466838          DOI: 10.1016/j.contraception.2017.01.001

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  37 in total

1.  Rapid activation of haemostasis after hormonal emergency contraception.

Authors:  Marianne van Rooijen; Angela Silveira; Stella Thomassen; Lars-Olof Hansson; Jan Rosing; Anders Hamsten; Katarina Bremme
Journal:  Thromb Haemost       Date:  2007-01       Impact factor: 5.249

2.  Venous thrombosis, oral contraceptives and high factor VIII levels.

Authors:  K W Bloemenkamp; F M Helmerhorst; F R Rosendaal; J P Vandenbroucke
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

Review 3.  Effects of oral contraceptives on hemostasis and thrombosis.

Authors:  J Rosing; G Tans
Journal:  Am J Obstet Gynecol       Date:  1999-06       Impact factor: 8.661

4.  Estimating systemic exposure to ethinyl estradiol from an oral contraceptive.

Authors:  Carolyn L Westhoff; Malcolm C Pike; Rosalind Tang; Marianne N DiNapoli; Monica Sull; Serge Cremers
Journal:  Am J Obstet Gynecol       Date:  2014-12-12       Impact factor: 8.661

5.  Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.

Authors:  Guido Tans; Astrid van Hylckama Vlieg; M Christella L G D Thomassen; Joyce Curvers; Rogier M Bertina; Jan Rosing; Frits R Rosendaal
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

6.  High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.

Authors:  M Besser; C Baglin; R Luddington; A van Hylckama Vlieg; T Baglin
Journal:  J Thromb Haemost       Date:  2008-08-01       Impact factor: 5.824

7.  High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism.

Authors:  A Tripodi; C Legnani; V Chantarangkul; B Cosmi; G Palareti; P M Mannucci
Journal:  J Thromb Haemost       Date:  2008-05-15       Impact factor: 5.824

Review 8.  Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.

Authors:  Madeleine Verhovsek; James D Douketis; Qilong Yi; Sanjay Shrivastava; R Campbell Tait; Trevor Baglin; Daniela Poli; Wendy Lim
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

9.  Fibrin fragment D-dimer and the risk of future venous thrombosis.

Authors:  Mary Cushman; Aaron R Folsom; Lu Wang; Nena Aleksic; Wayne D Rosamond; Russell P Tracy; Susan R Heckbert
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

10.  Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.

Authors:  Yana Vinogradova; Carol Coupland; Julia Hippisley-Cox
Journal:  BMJ       Date:  2015-05-26
View more
  1 in total

Review 1.  Impact of drugs on venous thromboembolism risk in surgical patients.

Authors:  Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič
Journal:  Eur J Clin Pharmacol       Date:  2019-02-05       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.